BRUSSELS, Nov 17 (Reuters) - ThromboGenics:
* Says has raised 42 million euros through a private placement of 2,641,778 new shares (9.99% of the outstanding shares)
* Says Belgian and international institutional and professional investors subscribed at a price of 16.00 euros per share (vs Monday close of 16.90 euros).
* Petercam acted as sole global coordinator, together with Jefferies International Limited and KBC Securities as joint bookrunners for the placing.
* Says funds will to commercialise lead product microplasmin, which is currently in a Phase III clinical trial for eye disorders.
((Philip Blenkinsop, Brussels newsroom; +32 2 287 6810))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says has raised 42 million euros through a private placement of 2,641,778 new shares (9.99% of the outstanding shares)
* Says Belgian and international institutional and professional investors subscribed at a price of 16.00 euros per share (vs Monday close of 16.90 euros).
* Petercam acted as sole global coordinator, together with Jefferies International Limited and KBC Securities as joint bookrunners for the placing.
* Says funds will to commercialise lead product microplasmin, which is currently in a Phase III clinical trial for eye disorders.
((Philip Blenkinsop, Brussels newsroom; +32 2 287 6810))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
